Lifeward Secures $5 Million in Direct Offering to Fuel Growth
Lifeward Ltd., known for its life-changing solutions, has recently announced a significant financial milestone. The company successfully closed a registered direct offering, raising $5 million through the issuance of ordinary shares priced at $2.75 each. This offering allows Lifeward to continue its mission of revolutionizing rehabilitation and recovery services.
Details of the Registered Direct Offering
The registered direct offering involved the sale of approximately 1,818,183 of Lifeward's ordinary shares. In addition to these shares, the company issued unregistered short-term warrants that provide the option to purchase an equivalent number of shares. These warrants come with a three-year term and can be exercised immediately at the same purchase price of $2.75.
Financial Impact and Proceeds Utilization
With this direct offering, Lifeward aims to bolster its commercial efforts and enhance working capital for ongoing projects. The gross proceeds are expected to advance the company’s overall strategy, ensuring it continues to deliver on its promise of innovation in rehabilitation technologies.
The Role of H.C. Wainwright & Co.
H.C. Wainwright & Co. served as the exclusive placement agent for this offering. Their expertise in facilitating such transactions is invaluable, ensuring that Lifeward’s financial strategies are aligned with its growth ambitions.
Warrants and Their Significance
The warrants issued during this process are noteworthy as they exemplify Lifeward’s strategy to engage investors in its growth story. These financial instruments not only offer immediate benefits but also signal confidence in Lifeward’s future performance and market presence.
Compliance and Regulatory Framework
The shares offered were sold under a shelf registration statement previously filed with the Securities and Exchange Commission (SEC). This established pathway allows Lifeward to streamline its capital-raising strategies while ensuring compliance with regulations.
About Lifeward
Founded in 2001, Lifeward designs innovative solutions that improve the quality of rehabilitation and recovery for individuals facing physical challenges. With operations extending across the United States, Israel, and Germany, Lifeward offers a diverse range of products. These include the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the MyoCycle FES System, and the ReStore Exo-Suit. Each product is designed to empower individuals to regain their independence and engage in activities they love.
Commitment to Innovation
Lifeward’s mission centers around relentless innovation and providing cutting-edge solutions. The company is dedicated to not only enhancing rehabilitation outcomes but also creating a supportive community for individuals with disabilities.
Future Aspirations
This recent offering positions Lifeward to further develop its innovative product portfolio and expand its market reach. By fostering advancements in rehabilitation technologies, Lifeward is committed to making a lasting difference in the lives of many.
Frequently Asked Questions
What was the amount raised in Lifeward's recent offering?
Lifeward raised $5 million through a registered direct offering of ordinary shares priced at $2.75 each.
Who acted as the placement agent for the offering?
H.C. Wainwright & Co. was the exclusive placement agent for Lifeward’s recent registered direct offering.
What will the proceeds from the offering be used for?
The proceeds will be utilized for ongoing commercial efforts, working capital, and general corporate purposes.
How many shares were offered in this direct offering?
A total of approximately 1,818,183 ordinary shares were offered in Lifeward's direct offering.
What is Lifeward's mission?
Lifeward's mission is to drive innovation and deliver life-changing solutions to individuals with physical limitations, enabling them to pursue their passions and enhance their quality of life.
